Physician profile
Luis J Navazo
NPI 1043359219
$162,244.38
in general payments reported to CMS, 2019-2025
64 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,776 · 2020: $3,909 · 2021: $15K · 2022: $25K · 2023: $45K · 2024: $31K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $20K · Travel and Lodging: $15K · Food and Beverage: $9,141 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,000 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,105.40 |
| Consulting Fee | $20,023.00 |
| Travel and Lodging | $14,548.75 |
| Food and Beverage | $9,141.48 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,000.00 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $78,256.85 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $61,020.33 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Kerecis Limited | $11,527.56 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Boston Scientific Corporation | $1,356.57 | 2024-2025 | Watchman Access System, Watchman, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $1,312.27 | 2019-2023 | |
| Lilly USA, LLC | $832.67 | 2019-2025 | Zepbound, Kisunla, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $709.43 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Alkermes, INC. | $542.54 | 2019-2023 | Aristada, Aristada Initio, Lybalvi |
| Organogenesis INC. | $462.59 | 2019-2025 | Puraply Wound Matrix |
| Otsuka America Pharmaceutical, INC. | $449.56 | 2023-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $364.86 | 2022-2025 | |
| Amarin Pharma, INC. | $350.32 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $347.68 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $329.23 | 2019-2024 | Yupelri |
| Abbvie INC. | $312.41 | 2021-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $284.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $252.29 | 2021-2023 | Verquvo |
| Acadia Pharmaceuticals INC | $244.32 | 2019-2025 | Nuplazid |
| Eisai INC. | $242.68 | 2021-2022 | |
| Astellas Pharma US INC | $234.20 | 2019-2022 | |
| Novo Nordisk INC | $223.88 | 2019-2024 | Ozempic, Rybelsus |
| Smith+Nephew, INC. | $169.69 | 2020-2025 | Collagenase Santyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.49 | 2021 | |
| Pfizer INC. | $142.32 | 2019-2024 | |
| Sanofi Pasteur INC. | $134.21 | 2020-2023 | |
| Indivior INC. | $133.79 | 2022-2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $128.35 | 2025 | Fanapt, Hetlioz |
| Seqirus USA INC | $119.29 | 2022-2024 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Lundbeck LLC | $116.81 | 2023-2025 | Rexulti |
| Philips North America LLC | $111.51 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $103.42 | 2023-2024 | Gemtesa |
| Amgen INC. | $101.14 | 2022 | |
| Advanced Respiratory, INC | $96.46 | 2021 | |
| Biogen, INC. | $90.26 | 2021-2022 | |
| Convatec INC. | $78.27 | 2025 | |
| Sunovion Pharmaceuticals INC. | $74.64 | 2019-2021 | |
| Corium, LLC | $65.10 | 2023 | Adlarity |
| Biohaven Pharmaceuticals, INC. | $59.82 | 2021 | |
| Allergan, INC. | $57.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $55.54 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Linus Health, INC. | $52.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.23 | 2019-2020 | |
| Braeburn INC. | $40.92 | 2025 | Brixadi |
| Baxter Healthcare | $37.55 | 2023 | Hillrom - Life 2000 Ventilation System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $35.00 | 2025 | |
| Biocryst US Sales Co., LLC | $34.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.14 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.62 | 2022-2023 | Quviviq |
| Abiomed | $27.72 | 2025 | |
| Viatris Specialty LLC | $25.23 | 2025 | Yupelri |
| Celgene Corporation | $23.61 | 2019 | |
| Lifenet Health | $22.55 | 2023 | |
| Orexo US, INC. | $22.47 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.09 | 2022 | |
| Inari Medical, INC. | $21.62 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Breathe Technologies, INC. | $18.85 | 2019 | |
| Hydrofera LLC | $18.41 | 2024 | Hydrofera Blue |
| Reprise Biomedical, INC. | $18.32 | 2024 | Miro3d |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2019 | |
| Lucid Diagnostics INC. | $13.73 | 2023 | |
| Redhill Biopharma INC. | $12.93 | 2020 | |
| Tactile Systems Technology INC | $12.49 | 2021 | |
| Bioventus LLC | $12.35 | 2022 | |
| Medela LLC | $6.82 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$10,675.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Navazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.